<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574248</url>
  </required_header>
  <id_info>
    <org_study_id>000626</org_study_id>
    <nct_id>NCT01574248</nct_id>
  </id_info>
  <brief_title>Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema</brief_title>
  <official_title>Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema - a Mulitcenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals with heart disease or high blood pressure are often prescribed angiotensin
      converting enzyme (ACE) inhibitors to treat their disease. However, the use of ACE inhibitors
      can be associated with angioedema, a rare but life-threatening condition that causes swelling
      of the face and other body parts. This study will evaluate the effectiveness of the drug
      HOE-140 at decreasing symptoms of angioedema in people taking ACE inhibitors who develop the
      condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People who take ACE inhibitors may develop angioedema, a condition that causes itchy and
      painful swelling beneath the skin around the eyes, lips, tongue, throat, hands, or feet. In
      severe cases, the throat may swell, obstructing the airway and leading to breathing
      difficulty. ACE inhibitors prevent the breakdown of a natural chemical in the body called
      bradykinin. Increased levels of bradykinin, which can cause swelling, may contribute to the
      development of angioedema. Blocking bradykinin receptor cells prevents bradykinin from
      initiating swelling and may lead to a possible decrease in angioedema symptoms. The purpose
      of this study is to evaluate the effectiveness of HOE-140, a bradykinin receptor blocker, at
      reducing symptoms in people with ACE inhibitor-associated angioedema.

      This study will enroll people admitted to the emergency room or hospital who have a severe
      case of ACE inhibitor-associated angioedema. Participants will be randomly assigned to
      receive an injection of either HOE-140 or placebo. Initially, participants will undergo an
      electrocardiogram to measure the electrical activity of the heart. Then blood pressure
      measurements, blood collection, a physical exam to determine the extent and duration of
      swelling, and photographs of the swelling will occur at 2, 4, 8, 16, and 24 hours following
      the start of treatment. Questionnaires will be completed by study staff and participants to
      assess changes in angioedema symptoms and the extent of swelling. Participants will remain in
      the hospital for 24 to 48 hours, depending on the severity of their symptoms. Blood will be
      collected at a follow-up visit that will occur 7 days after the resolution of angioedema
      symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DSMC recommended discontinuation for futility and feasibility
  </why_stopped>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Resolution of Angioedema</measure>
    <time_frame>48 hours</time_frame>
    <description>Time interval between initiation of treatment and when there is no symptom, by visual analog scale &lt;1 cm. Data provided are for worst symptom.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Admission to Intensive Care Unit</measure>
    <time_frame>T0 to T48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Requirement for Intubation</measure>
    <time_frame>T0 to T48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Given Steroids</measure>
    <time_frame>T0 to T48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Given Histamine Receptor Type 1 (H1) and Type 2 (H2) Blockers</measure>
    <time_frame>T0 to T48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Given Epinephrine</measure>
    <time_frame>T0 to T48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>T0 to T48 hours</time_frame>
    <description>Average of blood pressure measurements from zero to forty-eight hours provided.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>ACE Inhibitor-associated Angioedema</condition>
  <arm_group>
    <arm_group_label>icatibant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous at time 0 and 6 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>icatibant</intervention_name>
    <description>Subcutaneous at time 0 and 6 hours</description>
    <arm_group_label>icatibant</arm_group_label>
    <other_name>Firazyr</other_name>
    <other_name>HOE140</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous at time 0 and 6 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has ongoing angioedema while taking an ACE inhibitor.

          -  The subject is between 18 and 80 years of age.

        Exclusion Criteria:

          -  The subject has had angioedema while not taking an ACE inhibitor.

          -  The subject's angioedema only involves the bowel.

          -  The subject is known to be pregnant or has a positive urine pregnancy test.

          -  The subject has started on an oral contraceptive within the last 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy J. Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006 Nov;26(4):725-37. Review.</citation>
    <PMID>17085287</PMID>
  </reference>
  <reference>
    <citation>Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996 Jul;60(1):8-13.</citation>
    <PMID>8689816</PMID>
  </reference>
  <reference>
    <citation>Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009 Sep;54(3):516-23. doi: 10.1161/HYPERTENSIONAHA.109.134197. Epub 2009 Jul 6.</citation>
    <PMID>19581505</PMID>
  </reference>
  <reference>
    <citation>Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998 Oct 29;339(18):1285-92.</citation>
    <PMID>9791144</PMID>
  </reference>
  <reference>
    <citation>Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008 Sep 4;359(10):1027-36. doi: 10.1056/NEJMcp0803977. Review.</citation>
    <PMID>18768946</PMID>
  </reference>
  <reference>
    <citation>Verresen L, Fink E, Lemke HD, Vanrenterghem Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int. 1994 May;45(5):1497-503.</citation>
    <PMID>8072263</PMID>
  </reference>
  <reference>
    <citation>Krieter DH, Grude M, Lemke HD, Fink E, Bönner G, Schölkens BA, Schulz E, Müller GA. Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin. Kidney Int. 1998 Apr;53(4):1026-35.</citation>
    <PMID>9551414</PMID>
  </reference>
  <reference>
    <citation>Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007 Jun;119(6):1497-503. Epub 2007 Apr 5.</citation>
    <PMID>17418383</PMID>
  </reference>
  <reference>
    <citation>Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. JAMA. 1997 Jul 16;278(3):232-3.</citation>
    <PMID>9218671</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <results_first_submitted>October 28, 2016</results_first_submitted>
  <results_first_submitted_qc>December 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2017</results_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Nancy J. Brown</investigator_full_name>
    <investigator_title>Chair Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>ACE inhibitor</keyword>
  <keyword>Angioedema</keyword>
  <keyword>Bradykinin</keyword>
  <keyword>Swelling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Bradykinin</mesh_term>
    <mesh_term>Kininogens</mesh_term>
    <mesh_term>Icatibant</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Icatibant</title>
          <description>30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
icatibant: Subcutaneous at time 0 and 6 hours</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subcutaneous at time 0 and 6 hours
Placebo: Subcutaneous at time 0 and 6 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing primary endpoint data</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Icatibant</title>
          <description>30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
icatibant: Subcutaneous at time 0 and 6 hours</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subcutaneous at time 0 and 6 hours
Placebo: Subcutaneous at time 0 and 6 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.3" spread="13.4"/>
                    <measurement group_id="B2" value="60.7" spread="10.8"/>
                    <measurement group_id="B3" value="58.9" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Resolution of Angioedema</title>
        <description>Time interval between initiation of treatment and when there is no symptom, by visual analog scale &lt;1 cm. Data provided are for worst symptom.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Icatibant</title>
            <description>30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
icatibant: Subcutaneous at time 0 and 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous at time 0 and 6 hours
Placebo: Subcutaneous at time 0 and 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Angioedema</title>
          <description>Time interval between initiation of treatment and when there is no symptom, by visual analog scale &lt;1 cm. Data provided are for worst symptom.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="24" upper_limit="48"/>
                    <measurement group_id="O2" value="24" lower_limit="6" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Admission to Intensive Care Unit</title>
        <time_frame>T0 to T48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Icatibant</title>
            <description>30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
icatibant: Subcutaneous at time 0 and 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous at time 0 and 6 hours
Placebo: Subcutaneous at time 0 and 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Admission to Intensive Care Unit</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Requirement for Intubation</title>
        <time_frame>T0 to T48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Icatibant</title>
            <description>30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
icatibant: Subcutaneous at time 0 and 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous at time 0 and 6 hours
Placebo: Subcutaneous at time 0 and 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Requirement for Intubation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Given Steroids</title>
        <time_frame>T0 to T48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Icatibant</title>
            <description>30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
icatibant: Subcutaneous at time 0 and 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous at time 0 and 6 hours
Placebo: Subcutaneous at time 0 and 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Given Steroids</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Given Histamine Receptor Type 1 (H1) and Type 2 (H2) Blockers</title>
        <time_frame>T0 to T48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Icatibant</title>
            <description>30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
icatibant: Subcutaneous at time 0 and 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous at time 0 and 6 hours
Placebo: Subcutaneous at time 0 and 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Given Histamine Receptor Type 1 (H1) and Type 2 (H2) Blockers</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Given Epinephrine</title>
        <time_frame>T0 to T48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Icatibant</title>
            <description>30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
icatibant: Subcutaneous at time 0 and 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous at time 0 and 6 hours
Placebo: Subcutaneous at time 0 and 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Given Epinephrine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>Average of blood pressure measurements from zero to forty-eight hours provided.</description>
        <time_frame>T0 to T48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Icatibant</title>
            <description>30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
icatibant: Subcutaneous at time 0 and 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous at time 0 and 6 hours
Placebo: Subcutaneous at time 0 and 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Average of blood pressure measurements from zero to forty-eight hours provided.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="13"/>
                    <measurement group_id="O2" value="133" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Icatibant</title>
          <description>30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
icatibant: Subcutaneous at time 0 and 6 hours</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subcutaneous at time 0 and 6 hours
Placebo: Subcutaneous at time 0 and 6 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>elevated troponin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>leukocytosis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>low sperm count</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy J. Brown, M.D.</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>6153438701</phone>
      <email>nancy.j.brown@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

